Market Intelligence, Clinical Progress, and High-Purity Reagents for mTORC1 Pathway Modulation and Cancer Therapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NPRL2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT & Cancer Mutants) | NPRL2 Recombinant Protein (full-length & mutant variants including FFEVF2 region mutations; sequence verified, high purity >95%, endotoxin <1 EU/µg) | View NPRL2 Products |
| Gene Delivery | NPRL2 Promise-ORF / Lentivirus; full-length ORF for stable cell line construction, puromycin selection | View NPRL2 Products |
| Benchmark Ab | Anti-NPRL2 Recombinant Antibody (research-grade rabbit monoclonal positive control for Western, ELISA, IP) | View NPRL2 Products |
| Validator | NPRL2 siRNA Set (for knockdown verification, synthetic lethality screening, functional rescue) | View NPRL2 Products |
| Mutant Panel | NPRL2 Cancer-Associated Mutants (including FFEVF2 variants; sequence verified) | View NPRL2 Products |
| Complex Partner: NPRL3 | NPRL3 Recombinant Protein (obligate heterotrimeric subunit for GATOR1 reconstitution) | View NPRL3 Products |
| Complex Partner: DEPDC5 | DEPDC5 Recombinant Protein (scaffold protein essential for GATOR1 stability and RagA/B GAP activity) | View DEPDC5 Products |
| Substrate: RagA/RagB | RagA/RagB Recombinant Proteins (GTPase substrates for GAP activity assays) | View RRAGA Products |
| Downstream: RPTOR | RPTOR (Raptor) Recombinant Protein (mTORC1 component for pathway readout and counter-screening) | View RPTOR Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GATOR1 Complex Assembly & GAP Activity Quantification | Full-length NPRL2, NPRL3, DEPDC5 proteins with verified binding interfaces; co-expression compatible; RagA/RagB substrates available |
| Cancer-Associated Loss-of-Function Mutant Validation | Defined mutation panel (FFEVF2 region) with sequence verified identity for negative control studies |
| Synthetic Lethality Screening | Validated siRNA set with scrambled control for specificity checks in cell viability assays |
| Lack of Reliable Positive Controls | Research-grade recombinant antibodies for assay standardization (Western, ELISA, IP) |
| Structural Biology Applications (cryo-EM, crystallography) | Endotoxin-controlled (<1 EU/µg), high-purity (>95%) proteins suitable for structural studies |
Live NPRL2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NPRL2 therapeutics is intensifying, with a paradigm shift from direct targeting of this tumor suppressor to exploiting synthetic lethality and GATOR1 pathway restoration. NPRL2, as a core subunit of the GATOR1 complex (DEPDC5-NPRL2-NPRL3), negatively regulates mTORC1 via its GAP activity on RagA/B. Loss-of-function mutations are heavily implicated in glioblastoma, NSCLC, ccRCC, and familial focal epilepsies. Major pharmaceutical players are focusing on biomarker-driven trials, deploying next-generation mTOR inhibitors and novel metabolic modulators tailored for NPRL2-deficient profiles. The next wave of R&D includes allosteric activators stabilizing the DEPDC5-NPRL2-NPRL3 complex, molecular glues, gene therapy (lentiviral/AAV-mediated restoration), and synthetic lethal combinations. As first-generation mTOR inhibitors face resistance limitations, these emerging modalities promise more durable responses.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Stabilizer / mTOR Inhibitor) | Academic & Discovery-Stage Biotech; Novartis, Pfizer | Glioblastoma, NSCLC, ccRCC, Epilepsy | Binding Assays (need high-purity WT & mutant proteins); Synthetic lethality screening (need siRNA/lentivirus) |
| Gene Therapy / Restoration | Academic Centers, Rare Disease Biotechs | Solid Tumors (3p21 loss), Focal Epilepsy | Functional Rescue Assay (need lentivirus for stable integration) |
| PROTAC / Degrader (Downstream Nodes) | Platform Biotech Companies | mTOR-Driven Cancers | Pathway Knockdown Validation (need siRNA) |
| Targeted Activator / Molecular Glue | Emerging Pharma | Metastatic Cancers | Complex Reconstitution (need matched DEPDC5, NPRL3) |
| Diagnostic IVD | Molecular Dx Companies | Prognosis, Patient Stratification | Antibody Specificity (need high-purity immunogens) |
Molecular Differentiation & Assay Strategy
NPRL2 as a non-enzymatic PPI node requires precise modulation of protein complex dynamics rather than occupancy-driven inhibition. Best-in-class drugs must meet differentiated criteria:
- Affinity & Binding Kinetics: Stabilization of GATOR1 heterotrimer or enhanced RagA/B interaction. Recommended assays: SPR/BLI for direct binding, MST for affinity determination.
- Delivery & Developability: Excellent cell membrane permeability and intracellular stability. Early screening with PAMPA and thermal shift assays (DSF/TSA).
- Mechanism of Action: Distinguish between GATOR1 stabilization and direct GAP enhancement. Requires in vitro RagA/B GTP hydrolysis assays and cellular pS6K1/p4EBP1 readouts.
- Safety & Selectivity: Cross-reactivity panel including NPRL3, SEPTIN2/7; CRISPR rescue experiments to exclude off-target effects.
- Mutant Validation: Use tumor-derived loss-of-function mutants (e.g., FFEVF2 variants) as negative controls. TarMart provides sequence-verified WT and mutant proteins for comparative studies.
TarMart Solution Highlights
- High-purity recombinant proteins: HEK293-expressed, >95% purity, <1 EU/µg endotoxin, sequence verified, theoretical MW matched. Full-length and mutant variants.
- Complex-matched reagents: DEPDC5, NPRL3, RagA/RagB proteins for GATOR1 reconstitution and GAP assays.
- Cellular tools: Lentivirus and siRNA sets for isogenic model construction and functional rescue.
- Standardized controls: Recombinant anti-NPRL2 antibodies for reproducible detection.